Professional Documents
Culture Documents
an overview
Kathleen Holloway
Technical Briefing Seminar
November 2009
Pakistan
Bangladesh
Burkino Faso
Senegal
Angola
Tanzania
0 10 20 30 40 50 60
% observed consultations where the diagnostic process was adequate
G ha na
C a m e ro o n
N ige ria
S uda n
T a nza nia
Z im ba bwe
A S IA
Yemen
Indo ne s ia
N e pa l
15 billion injections per year globally
L.A M E R . & C A R .
E l S a lv a do r
2.3-4.7 million infections of hepatitis B/C
J a m a ic a and up to 160,000 infections of HIV per
E a s t e rn C a ribe a n
year associated with injections
30
DDD per 1000 inh. per day
25
20
15
10
0
FR GR LU PT IT BE SK HR PL IS IE ES FI BG CZ SI SE HU NO UK DK DE LV AT EE NL
60
50
40
30
20
10
0
1982-1994 1995-2000 2001-2006
Sub-Saharan Africa (n=29-48) Lat. America & Carrib (n=5-13)
Middle East & C. Asia (n=4-8) East Asia & Pacific (n=7-11)
South Asia (n=6-12)
1. EXAMINE
Measure Existing
Practices
(Descriptive
Quantitative Studies)
improve
4. FOLLOW UP 2. DIAGNOSE
Measure Changes diagnosis Identify Specific
in Outcomes Problems and Causes
(Quantitative and Qualitative (In-depth Quantitative
Evaluation) and Qualitative Studies)
improve
intervention
3. TREAT
Design and Implement
Interventions
(Collect Data to
Measure Outcomes)
Educational: Managerial:
Inform or persuade Guide clinical practice
– Health providers – Information systems/STGs
– Consumers – Drug supply / lab capacity
Use of
Medicines
Economic: Regulatory:
Offer incentives Restrict choices
– Institutions – Market or practice controls
– Providers and patients – Enforcement
% Prescribing Injections
80
60
Pre
40 Post
20
0
Intervention Control
• Dispensing strategies
– course of treatment packaging, labelling, generic substitution
Guidelines + on-
site training + 4 14 21.4% 55.2% +33.8%
supervisory visits
Fees (complete control fee / Px 1-band item fee 2-band item fee
drug courses) n=12 n=10 n=11
0 20 40 60 80 100
• Drug registration
• Banning unsafe drugs - but beware unexpected results
– substitution of a second inappropriate drug after banning a first
inappropriate or unsafe drug
• Regulating the use of different drugs to different
levels of the health sector e.g.
– licensing prescribers and drug outlets
– scheduling drugs into prescription-only & over-the-counter
• Regulating pharmaceutical promotional activities
80%
District-wide monitoring
60% (both groups)
40%
20%
0%
1 3 5 7 9 11 13 15 17 19 21 23 25
Months
Comparison group Interactive group discussion
0 20 40 60 80 100
2007 (n>85) 2003 (n>90) % countries implementing policies
20 Increase
15
10
Percent change
-5
-10 Decrease
-15
-20
d ia e d al rk rg ry ly ia el y n ia ia ia d in s y m d lic K ce
l an oat eec lan tug ma ou ga Ita vak sra rwa ede str en ton lan pa and an giu lan ub U
an
I v l m l
Po Cr Gr Ire Por en mb un
H S lo o
N Sw Au lo Es Fi
n S
er er Be
e
Ic Rep Fr
D x e S h G
et h
Lu e
N ec
z
Th C
For Iceland, total data (including hospitals) are used Slide courtesy of Otto Cars, STRAMA, Sweden
20
Co-ordination programs and national campaigns
15
10
Percent change
-5
-10
-15
-20
d ia e d al rk rg ry ly ia el y n ia ia ia d in s y m d lic K e
l an oat eec lan tug ma ou ga Ita vak sra rwa ede str en ton lan pa and an giu lan ub U nc
a
I v rl rm e l
Po Cr Gr Ire Por en mb un
Sl
o o
N Sw Au lo Es Fi
n S e
Ic Rep Fr
D xe H S t he Ge B
e h
Lu e
N ec
z
Th C
For Iceland, total data (including hospitals) are used Slide courtesy of Otto Cars, STRAMA, Sweden
http://www.icium.org
• Resolution WHA60.16
– Urges Member States " to consider establishing and/or
strengthening…a full national programme and/or
multidisciplinary national body, involving civil society and
professional bodies, to monitor and promote the rational use
of medicines "
– WHO to support countries to implement resolution
Situational analysis
WHO facilitating
multi-stakeholder Develop
Modify
action in countries national plans
action plans
of action
• Components
– Medicines use surveys and activities
– Medicines policy framework
– Health system factors
• Service delivery & human resources, insurance, drug supply,
regulation, financial (dis)incentives
– Specific technical areas for RUM
• National program coordination, MTCs, EMLs, STGs, monitoring,
provider & consumer education, independent medicines info, AMR
• Data for each component
– Taken from key informant questionnaires & health facility survey,
identifying relevant data from coding system of questions
• Analysis for each component
– Compares actual practice against best practice, choosing solutions from
a menu of interventions